Company Overview:
Cipla is engaged in the Business of Pharmaceuticals. Cipla has a diversified product portfolio of 1,500+ products in 50+ dosage forms and 65 therapeutic categories.
Financial Results:
Cipla reported Total revenue for Q4FY25 of ₹ 7,019 Crore up from ₹14,932 Crore in Q4FY24, a rise of 9% y-o-y.
Total Expense for Q4FY25 of ₹5,514 Crore up from ₹5,153 Crore in Q4FY24, a rise of 7% y-o-y.
Net Profit of ₹1,214 Crore up 30% from ₹932 Crore in Q4FY24.
Earnings per Share is ₹15.13, up 30% from ₹11.63 in Q4FY24.
![](data:image/svg+xml;charset=utf-8,<svg height="1011px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
